# Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia

> **NCT02688140** · PHASE3 · COMPLETED · sponsor: **Technische Universität Dresden** · enrollment: 135 (actual)

## Conditions studied

- Acute Promyelocytic Leukemia

## Interventions

- **DRUG:** Arsenic trioxide
- **DRUG:** Idarubicin
- **DRUG:** Cytarabine
- **DRUG:** Tretinoin
- **DRUG:** Mitoxantrone
- **DRUG:** Mercaptopurine
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT02688140
- **Lead sponsor:** Technische Universität Dresden
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2025-01-20
- **Final completion:** 2025-01-20
- **Target enrollment:** 135 (ACTUAL)
- **Last updated:** 2025-02-26

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02688140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02688140, "Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02688140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*